Dear Dr. Roach: About eight years ago, I was diagnosed with CIDP (chronic inflammatory demyelinating polyneuropathy). After several tests, it was diagnosed by a spinal tap.
One of the effects of this disease is that one鈥檚 toes feel as if they are asleep, and in my case, it made my legs very weak and affected my balance. About two years ago, I began having that same tingling in my fingers. 聽
The doctor assigned to my case really didn鈥檛 know what to do to treat this relatively rare disease, so he started me out on steroids intravenously for a few weeks and then he prescribed the medication CellCept. As I am in an area where there seems to be no doctor that is really familiar with the disease, I wonder if I should still be taking that medication. Also, is there any progress being made toward finding a cure for this disease? I am now 86 and have learned to cope, but I am more concerned with younger people who get this disease, since it is very debilitating.
If there is a cure for CIDP, I was not made aware of it.
D.M.
CIDP is a condition where nerves are compromised by damage to the myelin, a protein that envelops and protects nerves and improves nerve conduction. Damage to the myelin causes weakness (your legs are weak) and sensory abnormalities (the toes feel asleep). Balance problems, like you have, occur less commonly. The nerves to bladder and bowel may be affected in more-severe cases.
So far, I could be describing Guillain-Barre syndrome. The difference between Guillain-Barre syndrome and CIDP is that while GBS gets better over a few weeks, CIDP lasts longer than eight weeks. Some people with CIDP, mostly younger, have intermittent episodes. Some progress over time; that includes mostly people in the older age group. CIDP is most common in older males. Its cause is unknown. Nerve-conduction studies, nerve biopsy and spinal fluid analysis all are used to make the diagnosis.
Treatment is done most commonly with prednisone (a medicine that has many side effects if given long term), immune globulin (expensive and often limited in supply) or plasma exchange (expensive and available only at referral centres). Only about 25 per cent of patients will have long-term complete remission from the condition. There will be some response in about 60 per cent, and about 15 per cent will have severe disability (unable to walk).
CellCept (mycophenolate) has been used for this condition, but it concerns me that you are using this second-line treatment and lack confidence that your doctor is expert in treatment of this condition. Rare and serious diseases require experience for best outcomes.
You can read much more about the condition at .
Dr. Roach regrets that he is unable to answer individual letters, but will incorporate them in the column whenever possible. Readers may email questions to [email protected].
